相关实验视频

Updated: Jul 21, 2025

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

针对α-synuclein聚合的药理干预引发了REM睡眠行为障碍和帕金森病早期发展

Lida Du¹, Xiaoli He², Xiaonuo Fan³

¹Institute of Molecular Medicine & Innovative Pharmaceutics, Qingdao University, Qingdao, China; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China.

Pharmacology & therapeutics

|July 27, 2023

概括

快速眼动睡眠行为障碍 (RBD) 可能预测帕金森病 (PD). 在RBD中准α-synuclein可能会减缓PD的进展,但需要更多的研究才能找到有效的治疗方法.

科学领域:

神经科学是一个神经科学.
睡眠医学睡眠医学
神经学神经学

背景情况:

快速眼动睡眠行为障碍 (RBD) 是一种睡眠障碍,其特点在于在REM睡眠期间进行梦想.
RBD通常在帕金森病 (PD) 的临床诊断之前几年.
大脑干中的α-synuclein聚合与RBD和PD病变发生有关.

研究的目的:

审查α-synuclein神经退行,睡眠障碍和RBD之间的双向关系.
探索RBD作为PD早期生物标志物的潜力.
讨论RBD和PD的当前和新兴药理干预措施.

主要方法:

关于RBD,PD和α-synuclein的研究的文献综述.
分析RBD,α-synuclein聚合和神经元亡之间的相关性.
对治疗RBD和PD的药理学策略的评估.

主要成果:

在RBD发育,α-synuclein聚合和脑干区域的神经元亡之间存在强烈的相关性.
由于有效的治疗和试验有限,目前缺乏PD诱导的RBD的治疗指南.
研究了RBD和PD干预措施之间的双向治疗效应.

结论:

RBD作为帕金森病的潜在前性生物标志物.
针对RBD中的α-synuclein聚合可能为PD早期干预提供了一种策略.
进一步的研究对于开发有效的向治疗方法至关重要,既针对RBD和PD,考虑到它们的相互联系.

关键词:

帕金森病的疾病.药理干预措施药理干预措施雷姆睡眠行为障碍雷姆睡眠行为障碍 α-Synuclein神经退行症的发生

更多相关视频

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

相关概念视频

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Management of Insomnia

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...